The verdict
Our read at a glance.
Whether early senolytic research in specific diseases supports the broad anti-aging and healthspan claims, and self-directed use, of dasatinib-quercetin, fisetin, and similar compounds.
- The signal
- Animal studies show clearing senescent cells can improve healthspan, and small early human trials of dasatinib plus quercetin in conditions such as lung fibrosis and diabetic kidney disease have shown some target engagement and preliminary signals. Larger aging-focused trials, including of fisetin, are ongoing. There is no approval for anti-aging use.
- The unknown
- Whether senolytics produce meaningful long-term health benefits in people, which compounds and schedules work, and the safety of repurposing a cancer drug like dasatinib for healthy aging.
- Our read
- A plausible aging strategy still in early human testing, not a ready anti-aging treatment. Senolytics have strong animal data and early human signals in specific diseases, but the broad anti-aging claims and self-dosing run far ahead of the evidence, especially given dasatinib's risks.
The mechanism
How it works.
Senolytics are drugs and plant compounds meant to selectively kill senescent cells, aged cells that stop dividing but linger and leak inflammatory signals. Senescent cells survive by switching on anti-apoptotic defenses, and these compounds disable those defenses: the cancer drug dasatinib blocks SRC and related survival kinases, while the flavonoids quercetin and fisetin block BCL-2 family proteins that normally hold off cell death, so the cells self-destruct. Clearing them improves healthspan and lifespan in mice, but in people this rests on animal data plus small early trials in specific diseases, with no proof of broad anti-aging benefit.
Safety & regulatory boundary
The consequential part.
Senolytics are not approved as anti-aging treatments. Dasatinib is a prescription cancer drug with real side effects, and using it or other senolytics outside trials is not established or clearly safe. Animal and early human findings do not establish broad anti-aging benefit, and self-directed gray-market use is not the studied approach.
What's next
What we're watching.
Results of larger senolytic aging trials, which compounds and schedules prove useful, and safety in healthy people.
Context
Why this is discussed.
Senolytics test the idea that clearing aged cells could treat age-related disease, which drives strong interest and some self-experimentation.
The evidence base
20 cited references.
Registered trials8
ClinicalTrials.gov · PHASE2 · ENROLLING_BY_INVITATION · 2016-07
ClinicalTrials.gov · PHASE2 · ACTIVE_NOT_RECRUITING · 2025-12-04
ClinicalTrials.gov · PHASE1/PHASE2 · RECRUITING · 2026-03-24
ClinicalTrials.gov · PHASE2 · ACTIVE_NOT_RECRUITING · 2023-09-06
ClinicalTrials.gov · PHASE1 · NOT_YET_RECRUITING · 2026-09-01
ClinicalTrials.gov · PHASE2 · ACTIVE_NOT_RECRUITING · 2022-06-06
ClinicalTrials.gov · PHASE2 · RECRUITING · 2024-09-30
ClinicalTrials.gov · PHASE2 · ACTIVE_NOT_RECRUITING · 2021-12-22
Indexed literature (PubMed)12
Kirkland JL et al. · J Intern Med · 2020
Islam MT et al. · Aging Cell · 2023
Xu M et al. · Nat Med · 2018
Chaib S et al. · Nat Med · 2022
Zhang L et al. · FEBS J · 2023
Zhu Y et al. · Aging Cell · 2015
Guo X et al. · Phytomedicine · 2024
Rattanaprukskul K et al. · J Dent Res · 2025
Kirkland JL et al. · EBioMedicine · 2017
McHugh D et al. · Nat Rev Drug Discov · 2025
Zhang P et al. · Nat Neurosci · 2019
Novais EJ et al. · Nat Commun · 2021
Keep reading